BiondVax Pharmaceuticals Universal Flu Vaccine
Prepare to have your mind blown. A tiny little company called BiondVax Pharmaceuticals claims to have a flu immunization shot which will protect against future flu strains that don’t even exist yet! Sounds crazy but if this company really has produced a next generation flu shot capable of being a universal flu vaccine, the stock in this company is going to explode higher.
Flu vaccines are a $4.3 billion market. Current flu vaccines are limited to just 3 or 4 existing strains. Furthermore, seasonal flu vaccine effectiveness is only about 40% on average and as low as 9% in the elderly who are the most at risk group. Conversely, as a universal flu vaccine candidate, M-001 from BiondVax Pharmaceuticals is designed to provide improved and broad protection against all current and future seasonal and pandemic flu strains. The company published a paper in the journal Vaccine on their universal flu vaccine candidate M-001 where they showed the results of an immunization with M-001 prior to trivalent influenza vaccine in 2011-2012 and how it enhanced a protective immune responses against the 2014-2015 epidemic strain.
The Vaccine article reports that blood plasma samples from people who received M-001 in 2011 (as part of BiondVax’s BVX-005 clinical trial in the elderly) showed significantly increased protective antibodies against the new epidemic 2014-2015 flu strain, a strain which did not exist when M-001 was administered to the BVX-005 participants!
BiondVax Pharmaceuticals Stock Chart
Latest posts by Lance Jepsen
- Everest Re Group Stock Swing Long Setup On Momentum Squeeze - August 21, 2017
- No Institutional Selling Detected Last Week - August 20, 2017
- Moving Averages and High Low Index Signals - August 20, 2017